These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 31200861)

  • 1. Monitoring and deciphering protein degradation pathways inside cells.
    Daniels DL; Riching KM; Urh M
    Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
    Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
    ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
    Mahan SD; Riching KM; Urh M; Daniels DL
    Methods Mol Biol; 2021; 2365():151-171. PubMed ID: 34432243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
    Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
    J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
    Gu S; Cui D; Chen X; Xiong X; Zhao Y
    Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
    Li X; Song Y
    J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
    Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
    J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted protein degradation by PROTACs.
    Neklesa TK; Winkler JD; Crews CM
    Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delineating the role of cooperativity in the design of potent PROTACs for BTK.
    Zorba A; Nguyen C; Xu Y; Starr J; Borzilleri K; Smith J; Zhu H; Farley KA; Ding W; Schiemer J; Feng X; Chang JS; Uccello DP; Young JA; Garcia-Irrizary CN; Czabaniuk L; Schuff B; Oliver R; Montgomery J; Hayward MM; Coe J; Chen J; Niosi M; Luthra S; Shah JC; El-Kattan A; Qiu X; West GM; Noe MC; Shanmugasundaram V; Gilbert AM; Brown MF; Calabrese MF
    Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7285-E7292. PubMed ID: 30012605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROTAC-induced Protein Functional Dynamics in Targeted Protein Degradation.
    Chang CA; Wu KY; Hung TI
    bioRxiv; 2024 Jun; ():. PubMed ID: 38746111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization.
    Schwalm MP; Krämer A; Dölle A; Weckesser J; Yu X; Jin J; Saxena K; Knapp S
    Cell Chem Biol; 2023 Jul; 30(7):753-765.e8. PubMed ID: 37354907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
    Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
    Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach.
    Chen Q; Liu C; Wang W; Meng X; Cheng X; Li X; Cai L; Luo L; He X; Qu H; Luo J; Wei H; Gao S; Liu G; Wan J; Israel DI; Li J; Dou D
    ACS Chem Biol; 2023 Jan; 18(1):25-33. PubMed ID: 36606710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E3 ligase ligand chemistries: from building blocks to protein degraders.
    Sosič I; Bricelj A; Steinebach C
    Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTACs to address the challenges facing small molecule inhibitors.
    Martín-Acosta P; Xiao X
    Eur J Med Chem; 2021 Jan; 210():112993. PubMed ID: 33189436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
    Ocaña A; Pandiella A
    J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assays and technologies for developing proteolysis targeting chimera degraders.
    Liu X; Zhang X; Lv D; Yuan Y; Zheng G; Zhou D
    Future Med Chem; 2020 Jun; 12(12):1155-1179. PubMed ID: 32431173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.